A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by adjuvant chemotherapy as initial treatment of advanced stage (stage III/IV) ovarian, fallopian tube, and primary peritoneal cancer.
e17080Background: Ovarian cancer is the deadliest of gynecologic cancers. Cytoreductive surgery (CRS) is the cornerstone treatment for advanced stage ovarian cancer. Following CRS, hyperthermic int.